Alaska has recently implemented a Perinatal Hepatitis B case management program designed to identify, track, educate, and continue to further prevent HBV infection. The primary objectives of the perinatal program are:
- All pregnant women are tested for Hepatitis B Surface Antigen (HBsAg) as recommended by the American College of Obstetricians & Gynecologists and the CDC.
- Medical providers and delivery facilities are informed of the mothers HBsAg status.
- HBsAg-positive women are contacted before delivery and educated about HBV infection.
- Infants born to HBsAg-positive women receive Hepatitis B immune globulin (HBIG) and Hepatitis B vaccine within 12 hours of birth; complete the Hepatitis B series at recommended intervals.
- Infants born to HBsAg-positive mothers receive post-vaccination testing in a timely manner to ensure protection against HBV infection.
- A tracking system is used to ensure the infant receives appropriate post-exposure prophylaxis.
- Household and sexual contacts of HBsAg-positive women receive pre-vaccination testing, HBIG (if necessary) and Hepatitis B vaccine at recommended intervals.